What is the share price of Cipla Ltd (CIPLA) today?
The share price of CIPLA as on 17th April 2025 is ₹1515.20. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Cipla Ltd (CIPLA) share?
The past returns of Cipla Ltd (CIPLA) share are- Past 1 week: 3.64%
- Past 1 month: 1.03%
- Past 3 months: 5.05%
- Past 6 months: -2.35%
- Past 1 year: 12.46%
- Past 3 years: 49.05%
- Past 5 years: 158.83%
What are the peers or stocks similar to Cipla Ltd (CIPLA)?
The peers or stocks similar to Cipla Ltd (CIPLA) include:What is the dividend yield % of Cipla Ltd (CIPLA) share?
The current dividend yield of Cipla Ltd (CIPLA) is 0.86.What is the market cap of Cipla Ltd (CIPLA) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Cipla Ltd (CIPLA) is ₹122074.18 Cr as of 17th April 2025.What is the 52 week high and low of Cipla Ltd (CIPLA) share?
The 52-week high of Cipla Ltd (CIPLA) is ₹1702.05 and the 52-week low is ₹1317.25.What is the PE and PB ratio of Cipla Ltd (CIPLA) stock?
The P/E (price-to-earnings) ratio of Cipla Ltd (CIPLA) is 29.62. The P/B (price-to-book) ratio is 4.55.Which sector does Cipla Ltd (CIPLA) belong to?
Cipla Ltd (CIPLA) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Cipla Ltd (CIPLA) shares?
You can directly buy Cipla Ltd (CIPLA) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Cipla Ltd
CIPLA Share Price
CIPLA Share Price Chart
How to use scorecard? Learn more
CIPLA Performance & Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
24.47 | 4.55 | 0.86% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
49.39 | 6.29 | 0.54% |
CIPLA Analyst Ratings & Forecast
Detailed Forecast from 33 analysts
Price Upside
Earnings Growth
Rev. Growth
CIPLA Company Profile
Cipla Limited is a pharmaceutical company. The Company offers its products for the therapeutic areas, including cardiovascular, children's health, dermatology & cosmetology, diabetes, HIV/AIDS, infectious diseases & critical care, malaria etc.
Investor Presentation
View olderCIPLA Similar Stocks (Peers)
Compare with peersCIPLA Sentiment Analysis
CIPLA Stock Summary · January 2025
Cipla's recent performance reflects a blend of robust growth and operational challenges, with record quarterly revenues of 7,073 crores driven by strong contributions from the EMEU and One Africa segments. The company is strategically investing nearly $100 million to enhance its US manufacturing capabilities, aiming to mitigate supply chain disruptions and regulatory hurdles that have impacted product launches, particularly for Advair and Abraxane. While EBITDA margins remain healthy at 28%, management acknowledges that sustaining this level may be difficult due to seasonal fluctuations and competitive pricing pressures. Despite these challenges, optimism persists regarding future growth, particularly in the consumer wellness and respiratory segments, supported by ongoing innovation and potential acquisitions. Overall, Cipla is poised for long-term success, leveraging its operational efficiencies and strategic investments to navigate the evolving market landscape.
Key Points on Cipla Stock
CIPLA Stock Growth Drivers
8Strong Financial Performance
Cipla Limited reported record quarterly revenue of 7,073 crores, reflecting an 8% year-on-year growth, primarily
Investment in Manufacturing and Innovation
The company has invested nearly $100 million in capital expenditures to enhance its US manufacturing
CIPLA Stock Challenges
6Regulatory Delays and Approval Uncertainty
Cipla Limited is currently awaiting FDA approval for the Abraxane product, with a potential launch
Slowdown in Growth and Revenue Challenges
The company has acknowledged a slowdown in growth in its trade generic business, with growth
CIPLA Forecasts
Price
Revenue
Earnings
CIPLA Share Price Forecast
All values in ₹
All values in ₹
CIPLA Company Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
CIPLA Stock EPS (Earnings Per Share) Forecast
All values in ₹
All values in ₹
CIPLA
Income
Balance Sheet
Cash Flow
CIPLA Income Statement
Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 13,998.31 | 14,622.98 | 15,513.36 | 16,838.98 | 17,476.19 | 19,425.58 | 22,044.25 | 23,228.57 | 26,520.66 | 27,802.91 | ||||||||||
Raw Materials | 5,026.31 | 5,206.16 | 5,671.36 | 5,737.45 | 6,236.18 | 7,544.60 | 9,220.29 | 8,348.28 | 8,756.54 | 20,075.00 | ||||||||||
Power & Fuel Cost | 245.92 | 251.73 | 298.82 | 335.11 | 327.43 | 308.26 | 331.03 | 353.61 | 364.84 | |||||||||||
Employee Cost | 2,434.01 | 2,633.82 | 2,690.10 | 2,856.53 | 3,027.01 | 3,251.83 | 3,529.91 | 3,830.08 | 4,310.04 | |||||||||||
Selling & Administrative Expenses | 1,904.00 | 2,157.79 | 2,353.98 | 2,734.65 | 2,895.69 | 2,417.36 | 3,141.75 | 3,502.92 | 3,829.37 | |||||||||||
Operating & Other expenses | 1,700.19 | 1,669.00 | 1,392.59 | 1,601.36 | 1,439.69 | 1,385.11 | 1,169.70 | 1,873.68 | 2,417.07 | |||||||||||
EBITDA | 2,687.88 | 2,704.48 | 3,106.51 | 3,573.88 | 3,550.19 | 4,518.42 | 4,651.57 | 5,320.00 | 6,842.80 | 7,727.91 | ||||||||||
Depreciation/Amortization | 754.22 | 1,322.93 | 1,322.82 | 1,326.31 | 1,174.65 | 1,067.66 | 1,051.95 | 1,172.11 | 1,051.02 | 1,086.56 | ||||||||||
PBIT | 1,933.66 | 1,381.55 | 1,783.69 | 2,247.57 | 2,375.54 | 3,450.76 | 3,599.62 | 4,147.89 | 5,791.78 | 6,641.35 | ||||||||||
Interest & Other Items | 206.63 | 159.38 | 114.23 | 168.43 | 197.36 | 160.70 | 106.35 | 109.54 | 89.88 | 65.58 | ||||||||||
PBT | 1,727.03 | 1,222.17 | 1,669.46 | 2,079.14 | 2,178.18 | 3,290.06 | 3,493.27 | 4,038.35 | 5,701.90 | 6,575.77 | ||||||||||
Taxes & Other Items | 367.04 | 215.78 | 258.93 | 551.44 | 631.66 | 885.19 | 976.52 | 1,236.44 | 1,580.35 | 1,586.05 | ||||||||||
Net Income | 1,359.99 | 1,006.39 | 1,410.53 | 1,527.70 | 1,546.52 | 2,404.87 | 2,516.75 | 2,801.91 | 4,121.55 | 4,989.72 | ||||||||||
EPS | 16.93 | 12.52 | 17.53 | 18.97 | 19.19 | 29.82 | 31.20 | 34.72 | 51.06 | 61.80 | ||||||||||
DPS | 2.00 | 2.00 | 3.00 | 3.00 | 4.00 | 5.00 | 5.00 | 8.50 | 13.00 | 13.00 | ||||||||||
Payout ratio | 0.12 | 0.16 | 0.17 | 0.16 | 0.21 | 0.17 | 0.16 | 0.24 | 0.25 | 0.21 |
CIPLA Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFInvestor Presentation
CIPLA Past Performance & Peer Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Cipla Ltd | 29.62 | 4.55 | 0.86% |
Sun Pharmaceutical Industries Ltd | 43.78 | 6.25 | 0.77% |
Torrent Pharmaceuticals Ltd | 66.34 | 16.03 | 0.86% |
Mankind Pharma Ltd | 55.55 | 11.10 | — |
CIPLA Stock Price Comparison
Compare CIPLA with any stock or ETFCIPLA Shareholdings
CIPLA Promoter Holdings Trend
In last 6 months, promoter holding in the company has decreased by 1.72%
Pledged promoter holdings is insignificant
CIPLA Institutional Holdings Trend
In last 3 months, retail holding in the company has almost stayed constant
In last 3 months, foreign institutional holding of the company has decreased by 2.15%
CIPLA Shareholding Pattern
CIPLA Shareholding History
Mutual Funds Invested in CIPLA
In last 3 months, mutual fund holding of the company has increased by 2.98%
Top 5 Mutual Funds holding Cipla Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 2.2683% | Percentage of the fund’s portfolio invested in the stock 3.98% | Change in the portfolio weight of the stock over the last 3 months -0.45% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 7/67 (-2) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.9444% | Percentage of the fund’s portfolio invested in the stock 1.23% | Change in the portfolio weight of the stock over the last 3 months 0.31% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 19/150 (+3) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.6380% | Percentage of the fund’s portfolio invested in the stock 5.01% | Change in the portfolio weight of the stock over the last 3 months -0.24% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 5/59 (0) |
Compare 3-month MF holding change on Screener
smallcases containing CIPLA stock
A smallcase is a basket of stocks/ETFs that represents an idea or theme.Diversify your risk and buy smallcases that have Cipla Ltd
CIPLA Events
CIPLA Dividend Trend
CIPLA has increased or maintained dividend levels over the last 5 years
Current dividend yield is 0.86%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹8.60 every year
Dividends
Corp. Actions
Announcements
Legal Orders
CIPLA Upcoming Dividends
No upcoming dividends are available
CIPLA Past Dividends
Cash Dividend
Ex DateEx DateAug 2, 2024
Dividend/Share
₹13.00
Ex DateEx Date
Aug 2, 2024
Cash Dividend
Ex DateEx DateJul 21, 2023
Dividend/Share
₹8.50
Ex DateEx Date
Jul 21, 2023
Cash Dividend
Ex DateEx DateAug 8, 2022
Dividend/Share
₹5.00
Ex DateEx Date
Aug 8, 2022
Cash Dividend
Ex DateEx DateAug 9, 2021
Dividend/Share
₹5.00
Ex DateEx Date
Aug 9, 2021
Cash Dividend
Ex DateEx DateMar 19, 2020
Dividend/Share
₹1.00
Ex DateEx Date
Mar 19, 2020
CIPLA Stock News & Opinions
Cipla has allotted 23,282 fully paid-up equity shares of Rs 2 each, pursuant to exercise of employee stock options under the Employee Stock Option Scheme 2013-A of the Company. Consequently, the issued, subscribed and paid-up share capital of the Company stands increased to Rs 1,61,52,80,804 comprising of 80,76,40,402 equity shares of face value Rs 2 each.Powered by Capital Market - Live
Cipla's formulation is an AB-rated therapeutic equivalent of Abraxane and is indicated for the treatment of metastatic breast cancer, advanced or metastatic non-small cell lung cancer (NSCLC), and metastatic pancreatic cancer. The product is expected to be launched in the United States of America during the first half of fiscal year 2025'26, it added. Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolios in our home markets of India, South Africa, North America, and key regulated and emerging markets. The pharma major's consolidated net profit jumped 48.73% to Rs 1,570.51 crore in Q3 FY25 as against Rs 1,055.90 crore reported in Q3 FY24. Total revenue from operations grew by 7.10% year on year (YoY) to Rs 7,072.97 crore in the quarter ended 31 December 2024.Powered by Capital Market - Live
Cipla has received final approval from the United States Food and Drug Administration (USFDA) for the Abbreviated New Drug Application (ANDA) submitted for Paclitaxel Protein-bound Particles for Injectable Suspension (albumin-bound), 100 mg/vial, Single-Dose Vial (Protein-bound Paclitaxel) on 10 April 2025. Cipla's Protein-bound Paclitaxel is an AB-rated generic therapeutic equivalent version of Bristol Myers Squibb's Abraxane' for Injectable Suspension 100 mg/vial. Protein-bound Paclitaxel is indicated for the treatment of metastatic breast cancer, locally advanced or metastatic non-small cell lung cancer ('NSCLC') and metastatic adenocarcinoma of the pancreas. The product is expected to be launched in H1 FY 2025-26 in the United States of America.Powered by Capital Market - Live
Cipla will hold a meeting of the Board of Directors of the Company on 13 May 2025.Powered by Capital Market - Live
Cipla has classified its current Good Manufacturing Practices (cGMP) inspection of the company's manufacturing facility in Virgonagar, Bengaluru, conducted between 7 - 13 November 2024, as Voluntary Action Indicated (VAI). Powered by Capital Market - Live
Cipla will invest approx. ZAR 900 million in equity share capital of Cipla Medpro South Africa Proprietary Limited, a wholly-owned subsidiary of the Company in South Africa (CMSA). CMSA, is a wholly owned subsidiary of Cipla, and is the holding company for the group operations in South Africa. The group is involved in the manufacturing, marketing, and supply of pharmaceutical products. The investment will be utilised to reduce inter-group debt and improve the capital structure of CMSA and its subsidiaries. Powered by Capital Market - Live
Cipla Ltd gained for a third straight session today. The stock is quoting at Rs 1456.1, up 2.26% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.42% on the day, quoting at 23261.2. The Sensex is at 76748.82, up 0.28%. Cipla Ltd has slipped around 4.77% in last one month. Meanwhile, Nifty Pharma index of which Cipla Ltd is a constituent, has slipped around 8.79% in last one month and is currently quoting at 21163.9, up 0.9% on the day. The volume in the stock stood at 10.82 lakh shares today, compared to the daily average of 14.63 lakh shares in last one month. The benchmark January futures contract for the stock is quoting at Rs 1462.15, up 2.87% on the day. Cipla Ltd is up 7.78% in last one year as compared to a 7.07% spurt in NIFTY and a 19.04% spurt in the Nifty Pharma index.The PE of the stock is 24.71 based on TTM earnings ending December 24.Powered by Capital Market - Live
Net profit of Cipla rose 48.74% to Rs 1570.51 crore in the quarter ended December 2024 as against Rs 1055.90 crore during the previous quarter ended December 2023. Sales rose 7.01% to Rs 6961.60 crore in the quarter ended December 2024 as against Rs 6505.66 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales6961.606505.66 7 OPM %28.5726.86 - PBDT2195.891902.06 15 PBT1916.091668.63 15 NP1570.511055.90 49 Powered by Capital Market - Live
Total revenue from operations grew by 7.10% year on year (YoY) to Rs 7,072.97 crore in the quarter ended 31 December 2024. Profit before tax was at Rs 1,916.09 crore in the December quarter of FY25, up 30% from Rs 1,473.81 crore recorded in Q3 FY24. EBITDA in Q3 FY25 stood at Rs 1,989 crore, registering a growth of 15.7% on YoY basis. EBITDA margin improved to 28.1% as compared to 26.3% recorded in the corresponding quarter previous year. In Q2 FY25, One India Business grew at a healthy 10% YoY. The branded prescription business continued to outpace the market growth in key therapies, Trade Generics is back on a growth trajectory, and Anchor brands of CHL continued to grow bigger. The North America business delivered quarterly revenue of $226 million, supported by traction in differentiated assets that helped to overcome the Lanreotide supply shortfall. The business also received various generic drug approvals, including phenytonadione injectable 1 mg/0.5 ml, esomeprazole granules 2.5 mg/5 ml, and potassium phosphate injection USP. One Africa recorded a strong growth of 9% YoY in USD terms. In the private market, secondary growth was at a healthy 8.8% versus the market growth of 2.0%. The deep market focus strategy in emerging markets and Europe has laid a strong foundation, resulting in a 20% growth in USD terms. This growth was driven by an uptick in both the DTM and B2B categories, while overall margins remained sustained. Research and development (R&D) investments stood at Rs 360 crore, representing 5.1% of sales. This was driven by product filings and ongoing development efforts. The company reported a net cash position of Rs 8,947 crore. The debt primarily consists of lease liabilities and working capital requirements. Umang Vohra, MD and Global CEO at Cipla, said, 'I am pleased to share that we continue to make considerable progress across our focused markets. In Q3 FY25, we delivered growth across all our various geographies, despite a supply challenge in the U.S. We recorded a revenue growth of 8% over last year with the highest-ever EBITDA margin of 28.1%, driven by mix and other operational efficiencies. Our One-India business grew at a healthy 10% YoY. Key therapies in the branded prescription business continued to outpace the market growth, Trade Generics business growth trajectory is back on track, and Anchor brands in the consumer health business maintained leadership positions. With a positive traction in our differentiated assets, the US business posted revenue of $226 million. In South Africa, we recorded a solid growth of 21% YoY in local currency terms. Emerging markets and Europe delivered substantial revenue growth of 20% YoY on the back of a deep market focus strategy. Going ahead, the focus will be on growing our key markets, further building our flagship brands, investing in future pipelines, as well as focusing on resolutions on the regulatory front.'. Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolios in our home markets of India, South Africa, North America, and key regulated and emerging markets. Powered by Capital Market - Live
In a regulatory filing, the pharmaceutical major informed that the US FDA had conducted an inspection at the manufacturing facility of Medispray Laboratories (Medispray) located in Kundaim, Goa, from 14th to 20th of January 2025. On conclusion of the inspection, Medispray received one observation in Form 483. The company will work closely with the USFDA and remains committed to address these observations comprehensively within stipulated time, Cipla said in a statement. Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. The scrip lost 0.52% to end at Rs 1438.35 on the BSE today. Powered by Capital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 9.51%, vs industry avg of 9.04%
Over the last 5 years, market share decreased from 7.67% to 6.95%
Over the last 5 years, net income has grown at a yearly rate of 21.96%, vs industry avg of 15.28%